{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:26:46Z","timestamp":1792175206935,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09736-x","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:16:54Z","timestamp":1777598214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ivermectin therapy is associated with changes in SARS-CoV-2 RNA load in asymptomatic patients: a randomized controlled trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Hussein","family":"Mouawia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Bou","family":"Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Mourad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwa","family":"Yaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al Saabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Seblani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9562-2934","authenticated-orcid":false,"given":"Houssam","family":"Raad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"2","key":"9736_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/fcp.12644","volume":"35","author":"RT Kinobe","year":"2021","unstructured":"Kinobe RT, Owens L. A systematic review of experimental evidence for antiviral effects of ivermectin and an in-silico analysis of ivermectin\u2019s possible mode of action against SARS-CoV-2. Fundam Clin Pharmacol. 2021;35(2):260\u201376.","journal-title":"Fundam Clin Pharmacol"},{"issue":"10","key":"9736_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102206","volume":"12","author":"NMS Sansone","year":"2024","unstructured":"Sansone NMS, Boschiero MN, Marson FAL. Efficacy of ivermectin, chloroquine\/hydroxychloroquine, and azithromycin in managing COVID-19: a systematic review of phase III clinical trials. Biomedicines. 2024;12(10):2206. https:\/\/doi.org\/10.3390\/biomedicines12102206.","journal-title":"Biomedicines"},{"issue":"9","key":"9736_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092100","volume":"9","author":"DA Jans","year":"2020","unstructured":"Jans DA, Wagstaff KM. Ivermectin as a broad-spectrum host-directed antiviral: the real deal? Cells. 2020;9(9):2100. https:\/\/doi.org\/10.3390\/cells9092100.","journal-title":"Cells"},{"key":"9736_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104760","volume":"177","author":"SNY Yang","year":"2020","unstructured":"Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin \u03b1\/\u03b21 heterodimer. Antiviral Res. 2020;177:104760. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104760.","journal-title":"Antiviral Res"},{"key":"9736_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.","journal-title":"Antiviral Res"},{"issue":"3","key":"9736_CR6","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s43440-020-00195-y","volume":"73","author":"H Kaur","year":"2021","unstructured":"Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep. 2021;73(3):736\u201349. https:\/\/doi.org\/10.1007\/s43440-020-00195-y.","journal-title":"Pharmacol Rep"},{"issue":"5","key":"9736_CR7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jiph.2024.03.030","volume":"17","author":"T Siripongboonsitti","year":"2024","unstructured":"Siripongboonsitti T, Tawinprai K, Avirutnan P, Jitobaom K, Auewarakul P. A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir\/Ivermectin\/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV). J Infect Public Health. 2024;17(5):897\u2013905. https:\/\/doi.org\/10.1016\/j.jiph.2024.03.030.","journal-title":"J Infect Public Health"},{"issue":"6","key":"9736_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27647","volume":"10","author":"Z Song","year":"2024","unstructured":"Song Z, Shi S, Zhang Y. Ivermectin for treatment of COVID-19: a systematic review and meta-analysis. Heliyon. 2024;10(6):e27647. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27647.","journal-title":"Heliyon"},{"issue":"11","key":"9736_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1001\/jama.2023.1922","volume":"329","author":"K Bibbins-Domingo","year":"2023","unstructured":"Bibbins-Domingo K, Malani PN. At a higher dose and longer duration, ivermectin still not effective against COVID-19. JAMA. 2023;329(11):897\u20138. https:\/\/doi.org\/10.1001\/jama.2023.1922.","journal-title":"JAMA"},{"issue":"1","key":"9736_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09563-y","volume":"24","author":"A Wijewickrema","year":"2024","unstructured":"Wijewickrema A, Banneheke H, Pathmeswaran A, Refai FW, Kauranaratne M, Malavige N, et al. Efficacy and safety of oral ivermectin in the treatment of mild to moderate COVID-19 patients: a multi-centre double-blind randomized controlled clinical trial. BMC Infect Dis. 2024;24(1):719. https:\/\/doi.org\/10.1186\/s12879-024-09563-y.","journal-title":"BMC Infect Dis"},{"key":"9736_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12879-021-06061-7","volume":"21","author":"N Okumu\u015f","year":"2021","unstructured":"Okumu\u015f N, Demirt\u00fcrk N, \u00c7etinkaya RA, G\u00fcner R, Avc\u0131 \u0130Y, Orhan S, et al. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID 19 patients. BMC Infect Dis. 2021;21:411. https:\/\/doi.org\/10.1186\/s12879-021-06061-7.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"9736_CR12","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s11357-023-00756-y","volume":"45","author":"Z Rag\u00f3","year":"2023","unstructured":"Rag\u00f3 Z, T\u00f3th B, Szalenko-T\u0151k\u00e9s \u00c1, Bella Z, Dembrovszky F, Farkas N, et al. Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection. GeroScience. 2023;45(4):2179\u201393. https:\/\/doi.org\/10.1007\/s11357-023-00756-y.","journal-title":"GeroScience"},{"key":"9736_CR13","doi-asserted-by":"publisher","unstructured":"Buonfrate D, Chesini F, Martini D, et al. High-dose ivermectin for early treatment of COVID-19 (COVER trial): a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2022. https:\/\/doi.org\/10.1093\/cid\/ciac688.","DOI":"10.1093\/cid\/ciac688"},{"issue":"11","key":"9736_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.42588","volume":"5","author":"D Komar","year":"2022","unstructured":"Komar D, et al. Effect of ivermectin on clinical outcomes in patients with COVID-19: a randomized clinical trial. JAMA Netw Open. 2022;5(11):e2242588. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.42588.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"9736_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0369","volume":"4","author":"S Thomas","year":"2021","unstructured":"Thomas S, Patel D, Bittel B, Wolski K, Wang Q, Kumar A, et al. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial. JAMA Netw Open. 2021;4(2):e210369. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0369.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"9736_CR16","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1002\/jmv.26812","volume":"93","author":"E Finzi","year":"2021","unstructured":"Finzi E, Harrington A. Zinc treatment of outpatient COVID-19: a retrospective review of 28 consecutive patients. J Med Virol. 2021;93(5):2588\u201390. https:\/\/doi.org\/10.1002\/jmv.26812.","journal-title":"J Med Virol"},{"issue":"2","key":"9736_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2020-001350","volume":"7","author":"JJ DiNicolantonio","year":"2020","unstructured":"DiNicolantonio JJ, Barroso J, McCarty M. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart. 2020;7(2):e001350. https:\/\/doi.org\/10.1136\/openhrt-2020-001350.","journal-title":"Open Heart"},{"issue":"4","key":"9736_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/jac\/dkz524","volume":"75","author":"M Navarro","year":"2020","unstructured":"Navarro M, Camprub\u00ed D, Requena-M\u00e9ndez A, Buonfrate D, Giorli G, Kamgno J, et al. Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020;75(4):827\u201334. https:\/\/doi.org\/10.1093\/jac\/dkz524.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"9736_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30883-5","volume":"21","author":"G Kampf","year":"2021","unstructured":"Kampf G, Lemmen S, Suchomel M. Ct values and infectivity of SARS-CoV-2 on surfaces. Lancet Infect Dis. 2021;21(6):e141. https:\/\/doi.org\/10.1016\/S1473-3099(20)30883-5.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"9736_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18178-1","volume":"11","author":"AS Dingens","year":"2020","unstructured":"Dingens AS, Crawford KHD, Adler A, Steele SL, Lacombe K, Eguia R, et al. Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. Nat Commun. 2020;11(1):4378. https:\/\/doi.org\/10.1038\/s41467-020-18178-1.","journal-title":"Nat Commun"},{"issue":"11","key":"9736_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006934","volume":"12","author":"TL Xu","year":"2018","unstructured":"Xu TL, Han Y, Liu W, Pang XY, Zheng B, Zhang Y, et al. Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus. PLoS Negl Trop Dis. 2018;12(11):e0006934. https:\/\/doi.org\/10.1371\/journal.pntd.0006934.","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"9736_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1017\/S0031182005009108","volume":"132","author":"MS Sajid","year":"2006","unstructured":"Sajid MS, Iqbal Z, Muhammad G, Iqbal MU. Immunomodulatory effect of various anti-parasitics: a review. Parasitology. 2006;132(3):301\u201313. https:\/\/doi.org\/10.1017\/S0031182005009108.","journal-title":"Parasitology"},{"issue":"20","key":"9736_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015471","volume":"24","author":"YF Yang","year":"2023","unstructured":"Yang YF, Singh S. Pharmacogenomic landscape of ivermectin and selective antioxidants: exploring gene interplay in the context of long COVID. Int J Mol Sci. 2023;24(20):15471. https:\/\/doi.org\/10.3390\/ijms242015471.","journal-title":"Int J Mol Sci"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09736-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09736-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09736-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T01:24:32Z","timestamp":1781745872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09736-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9736"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09736-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research protocol was reviewed and approved by the Ethics Committee operating under the accreditation of the Lebanese Ministry of Public Health at Rayak Hospital (approval number: GB-Fo-008\u20132019). Written informed consent was obtained from all participants in accordance with ethical standards prior to their participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no financial or non-financial competing interests related to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"447"}}